Patents by Inventor Mathew Edward SOWA
Mathew Edward SOWA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240044876Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: ApplicationFiled: March 30, 2023Publication date: February 8, 2024Inventors: Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
-
Patent number: 11644460Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: GrantFiled: December 21, 2020Date of Patent: May 9, 2023Assignee: Revolution Medicines, Inc.Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
-
Patent number: 11479797Abstract: The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.Type: GrantFiled: October 27, 2017Date of Patent: October 25, 2022Assignee: Ginkgo Bioworks, Inc.Inventors: Daniel C. Gray, Brian R. Bowman, Gregory L. Verdine, Mathew Edward Sowa
-
Publication number: 20220144849Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.Type: ApplicationFiled: June 11, 2021Publication date: May 12, 2022Inventors: Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
-
Publication number: 20220143202Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.Type: ApplicationFiled: June 10, 2021Publication date: May 12, 2022Inventors: Gregory Lawrence VERDINE, M. James NICHOLS, Dylan Talbot STILES, Neville John ANTHONY, Brian Roger BOWMAN, Mathew Edward SOWA, Sharon Ann TOWNSON
-
Publication number: 20220082556Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: ApplicationFiled: December 21, 2020Publication date: March 17, 2022Inventors: Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
-
Patent number: 11059830Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.Type: GrantFiled: December 2, 2019Date of Patent: July 13, 2021Assignee: Revolution Medicines, Inc.Inventors: Gregory Lawrence Verdine, Brian Roger Bowman, Mathew Edward Sowa, Joshua Alan Van Dyke Blodgett, Keith Earl Robison, Dylan Talbot Stiles, Jay Paul Morgenstern, Sharon Ann Townson, Uddhav Kumar Shigdel
-
Patent number: 10989710Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: GrantFiled: December 20, 2018Date of Patent: April 27, 2021Assignee: Revolution Medicines, Inc.Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
-
Publication number: 20200347074Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.Type: ApplicationFiled: December 2, 2019Publication date: November 5, 2020Inventors: Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
-
Patent number: 10533016Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.Type: GrantFiled: January 8, 2016Date of Patent: January 14, 2020Assignee: Revolution Medicines, Inc.Inventors: Gregory Lawrence Verdine, Brian Roger Bowman, Mathew Edward Sowa, Joshua Alan Van Dyke Blodgett, Keith Earl Robison, Dylan Talbot Stiles, Jay Paul Morgenstern, Sharon Ann Townson, Uddhav Kumar Shigdel
-
Publication number: 20190271691Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: ApplicationFiled: December 20, 2018Publication date: September 5, 2019Inventors: Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
-
Publication number: 20190249213Abstract: The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.Type: ApplicationFiled: October 27, 2017Publication date: August 15, 2019Inventors: Daniel C. GRAY, Brian R. BOWMAN, Gregory L. VERDINE, Mathew Edward SOWA
-
Patent number: 10203323Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: GrantFiled: August 2, 2016Date of Patent: February 12, 2019Assignee: Warp Drive Bio, Inc.Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
-
Publication number: 20180318434Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.Type: ApplicationFiled: July 16, 2018Publication date: November 8, 2018Inventors: Gregory Lawrence Verdine, M. James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
-
Publication number: 20180273544Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of the target protein. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of target protein activity.Type: ApplicationFiled: January 8, 2016Publication date: September 27, 2018Inventors: Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
-
Patent number: 10039839Abstract: The invention relates to macrocyclic compounds capable of modulating biological processes through binding to a presenter protein and a target protein. These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity. In some embodiment, the compounds of the invention “re-program” the binding of the presenter proteins to protein targets that either do not normally bind to the presenter protein.Type: GrantFiled: January 8, 2016Date of Patent: August 7, 2018Assignee: Warp Drive Bio, Inc.Inventors: Gregory Lawrence Verdine, Matthew James Nichols, Dylan Talbot Stiles, Neville John Anthony, Brian Roger Bowman, Mathew Edward Sowa, Sharon Ann Townson
-
Publication number: 20160341719Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: ApplicationFiled: August 2, 2016Publication date: November 24, 2016Inventors: Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
-
Patent number: 9428845Abstract: Disclosed herein are methods for identifying novel drug candidates.Type: GrantFiled: December 27, 2011Date of Patent: August 30, 2016Assignee: Warp Drive Bio, Inc.Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
-
Publication number: 20160199506Abstract: The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.Type: ApplicationFiled: January 8, 2016Publication date: July 14, 2016Inventors: Gregory Lawrence VERDINE, Matthew James NICHOLS, Dylan Talbot STILES, Neville John ANTHONY, Brian Roger BOWMAN, Mathew Edward SOWA, Sharon Ann TOWNSON